China National Biotec Group Company Limited

Quick facts

Marketed products

• coadministration · Other
• COVAX · Other
• COVAX+IIV4; COVAX+PPV23 · Immunology / Infectious Disease
  COVAX+IIV4 and COVAX+PPV23 are combination vaccines that provide immunization against COVID-19 (COVAX component) alongside seasonal influenza (IIV4) or pneumococcal disease (PPV23).
• COVAX only (1st and 2nd dose) · Immunology / Infectious Disease
  COVAX is an inactivated COVID-19 vaccine that stimulates the immune system to produce antibodies and cellular immunity against SARS-CoV-2 by presenting inactivated viral particles.
• COVAX+PPV23;COVAX+IIV4 · Immunology
• DTaP · Immunology
  DTaP is a combination vaccine that stimulates the immune system to produce antibodies against diphtheria toxin, tetanus toxin, and pertussis antigens.
• EV71 vaccine and influenza vaccine · Immunology / Infectious Disease
  This is a combination vaccine that stimulates the immune system to produce antibodies and cellular immunity against enterovirus 71 (EV71) and influenza viruses.
• HepA
• IIV4 and PPV23 · Immunology
  IIV4 and PPV23 are inactivated influenza and pneumococcal vaccines that stimulate the immune system to produce antibodies against influenza virus strains and Streptococcus pneumoniae serotypes.
• IIV4+PPV23 · Other
• Inactivated Polio Vaccine
• Sabin-IPV and DTaP
• sIPV · Immunology / Infectious Disease
  sIPV is an inactivated polio vaccine that stimulates the immune system to produce antibodies against poliovirus types 1, 2, and 3.
• sIPV+DTaP+HepA · Immunology / Infectious Disease Prevention
  This combination vaccine provides immunization against poliomyelitis, diphtheria, tetanus, pertussis, and hepatitis A through inactivated viral and bacterial antigens.
• sIPV+DTaP+MMR · Immunology / Infectious Disease Prevention
  This combination vaccine provides immunization against poliomyelitis, diphtheria, tetanus, pertussis, measles, mumps, and rubella through inactivated viral and bacterial antigens.

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• China National Biotec Group Company Limited portfolio CI brief
• China National Biotec Group Company Limited pipeline updates RSS

Frequently asked questions about China National Biotec Group Company Limited

Related

• coadministration · Other
• COVAX · Other
• COVAX+IIV4; COVAX+PPV23 · Immunology / Infectious Disease
• COVAX only (1st and 2nd dose) · Immunology / Infectious Disease
• COVAX+PPV23;COVAX+IIV4 · Immunology
• Sector hub: All tracked pharma companies